Gerresheimer AG stock (DE000A0LD6E6): Activist stake hits 15.19% amid product launch

Active Ownership Fund raised its stake in Gerresheimer AG to 15.19% through May 2026 purchases, coinciding with a new moisture-barrier packaging tech debut at Interpack.

Gerresheimer AG, a leading provider of pharmaceutical primary packaging and drug delivery systems, saw its investor base shift as the Luxembourg-based Active Ownership Fund increased its combined stake to 15.19% via purchases between May 4 and 6, 2026. The fund acquired roughly 42,500 shares at €24.99 on May 4, over 112,500 at €25.70 on May 5, and 15,750 at €25.85 on May 6, lifting the holding from 14.70%, according to ad-hoc-news.de as of May 2026. Concurrently, the company unveiled LeneX™ UltraGuard® with Milliken & Company at the Interpack trade fair, aiming to reduce moisture ingress in HDPE packaging by up to 40%.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Gerresheimer AG
• Sector/industry: Pharmaceutical packaging and drug delivery systems
• Headquarters/country: Düsseldorf, Germany
• Core markets: Europe, US, Asia
• Key revenue drivers: Primary packaging, injection systems
• Home exchange/listing venue: Xetra (GXI)
• Trading currency: EUR

Gerresheimer AG: core business model

Gerresheimer AG develops and manufactures glass and plastic primary packaging solutions plus drug delivery systems for the pharma and biotech industries. Its Plastics & Devices and Primary Packaging Glass divisions serve global clients with vials, syringes, inhalers, and ampoules. The company reported 2025 revenue guidance of €2.3-2.4 billion with an adjusted EBITDA margin of 18-19%, per its outlook as published in May 2026 updates via ad-hoc-news.de as of May 2026.

Headquartered in Düsseldorf, Gerresheimer employs over 10,000 people across 35+ sites worldwide, with significant US exposure through facilities like Centor Inc. This footprint positions it as a key supplier to American pharma giants amid rising demand for biologics packaging.

Main revenue and product drivers for Gerresheimer AG

Plastics & Devices contributes around 45% of revenue, driven by insulin pens, auto-injectors, and inhalers. Primary Packaging Glass adds 55%, focusing on vials and cartridges essential for vaccines and injectables. The recent LeneX™ UltraGuard® tech enhances HDPE bottles' stability for moisture-sensitive drugs, developed with Milliken, targeting cost savings and regulatory compliance.

US market relevance grows via Centor, a prescription packaging unit valued at €292 million at 2024 year-end, now up for sale advised by Morgan Stanley with multiple bidders, expected to close in 2026 according to ad-hoc-news.de as of May 2026.

Industry trends and competitive position

The global pharma packaging market, valued at $100+ billion, expands at 6-8% CAGR through 2030 per sector reports, fueled by biologics and personalized medicine. Gerresheimer competes with Schott, West Pharma, and Stevanda, holding ~10% share in glass vials. Its innovation in barrier tech addresses sustainability pressures, reducing material use—a boon for US firms under ESG mandates.

Gerresheimer AG faces regulatory scrutiny

BaFin initiated a probe on March 6, 2026, into Gerresheimer's interim statements over lease liabilities, development cost lives, and €196.5 million impairments in Advanced Technologies. Lenders extended deadlines to September 2026, waiving covenants pending June's audited annual report. APAS probes KPMG's 2024 audit on €35 million revenue recognition.

Why Gerresheimer AG matters for US investors

Listed on Xetra (GXI), Gerresheimer offers US investors indirect exposure to Europe's pharma supply chain with direct US operations like Centor. Its products support key American biotech growth, trading at levels reflecting recovery potential post-scrutiny, with Goldman Sachs holding 19.80% as of May 7, 2026 per aktiencheck.de as of May 2026.

Conclusion

Gerresheimer AG navigates activist stake builds and product innovations alongside BaFin probes and asset sales. With 2026 guidance intact and Centor divestiture progressing, the company eyes financial stabilization. US investors track its role in pharma packaging amid regulatory hurdles.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.